Artificial intelligence is moving beyond productivity to become something far more personal: a companion. As AI systems learn to listen, remember and respond empathetically, they could help address loneliness and provide valuable emotional support. Yet growing dependence on artificial relationships raises profound questions about social skills, emotional attachment, authenticity and human intimacy. The future challenge is not preventing machines from becoming better companions, but ensuring technology strengthens rather than replaces the human connections that give relationships meaning.
Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion, strengthening its pipeline with an experimental precision therapy targeting rare blood cancers. The transaction reflects Lilly’s accelerating biotech acquisition strategy as blockbuster medicines Mounjaro and Zepbound provide substantial financial firepower. By investing across oncology, hematology and other therapeutic areas, Lilly is seeking to diversify beyond diabetes and obesity treatments and build new sources of long-term growth through promising next-generation medicines and biotechnology platforms.
Our daily updates deliver a curated selection of top stories.